CLINICAL IMMUNOLOGY
Effects of reduced glutathione therapy on chronic hepatitis B
Submission date: 2015-12-30
Final revision date: 2016-04-24
Acceptance date: 2016-04-25
Publication date: 2017-02-16
Cent Eur J Immunol 2017;42(1):97-100
KEYWORDS
ABSTRACT
Developed chronic hepatitis B (CHB) causes death in approximately one million patients every year. Therefore, natural drugs with high therapeutic efficacy and minimal side effects must be developed for CHB treatment. This study aimed to relate the therapeutic effects of glutathione on CHB. A total of 104 CHB patients were randomly divided into two groups: the control group, which received an intravenous drip of 0.4 g of inosine injection with 250 ml of 5% glucose once a day for eight weeks, and the treatment group, which received an intravenous drip of 1200 mg of glutathione on the basis of the treatment of the control group. Glutathione treatment decreased the serum levels of asparaginic acid transaminase, alanine aminotransferase, total bilirubin, total bile acids, haluronic acid, collagen IV, laminin, transforming growth factor-β1, tumour necrosis factor-α, interleukin-6, and interleukin-8, compared with the control group. The results indicate that glutathione treatment can improve liver function and inhibit inflammation and hepatic fibrosis in CHB patients.
REFERENCES (21)
1.
Chan HL, Elkhashab M, Trinh H, et al. (2006): Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J Hepatol 63: 1086-1092.
2.
Lavanchy D (2004): Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepatitis 11: 97-107.
3.
Uhl P, Fricker G, Haberkorn U, Mier W (2014): Current status in the therapy of liver diseases. Int J Mol Sci 15: 7500-7512.
5.
Dröge W, Schulze-Osthoff K, Mihm S, et al. (1994): Functions of glutathione and glutathione disulfide in immunology and immunopathology. Faseb J 8: 1131-1138.
6.
Nakamura H, Nakamura K, Yodoi J (1997): Redox regulation of cellular activation. Annu Rev Immunol 15: 351-369.
7.
Rahman I (2000): Regulation of nuclear factor-kappaB, activator protein-1, and glutathione levels by tumor necrosis factor-alpha and dexamethasone in alveolar epithelial cells. Biochem Pharmacol 60: 1041-1049.
8.
Bilzer M, Baron A, Schauer R, et al. (2002): Glutathione treatment protects the rat liver against injury after warm ischemia and Kupffer cell activation. Digestion 66: 49-57.
9.
Bhandari S, Agarwal MP, Dwivedi S, Banerjee B (2008): Monitoring oxidative stress across worsening Child Pugh class of cirrhosis. Indian J Med Sci 62: 444-451.
10.
Kwon do Y, Jung YS, Kim SJ, et al. (2009): Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr 139: 63-68.
11.
Sora T (1998): Effects of combined glutathione and ursodeoxycholic acid therapy on chronic hepatitis C unresponsive to interferon. J Med Soc Toho U 45: 331-338.
12.
Salunga TL, Cui ZG, Shimoda S, et al. (2007): Oxidative stress induced apoptosis of bile duct cells in primary biliary cirrhosis. J Autoimmun 29: 78-86.
13.
Yang H, Ramani K, Xia M, et al. (2009): Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology 49: 1982-1991.
14.
Kria L, Ohira A, Amemiya T (1998): Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Graef Arch Clin Exp 9: 702-708.
15.
Wang J, Huang Q, Chen M (2003): The role of NF-kappaB in hepatocellular carcinoma cell. Chinese Med J 116: 47-752.
16.
Yu LL, Yu HG, Yu JP, Luo HS (2004): Nuclear factor-kappa B regulates cyclooxygenase-2 expression and cell proliferation inhuman colorectal carcinoma tissue. Exp Oncol 26: 40-47.
17.
Kiernan R, Brès V, Ng RW, et al. (2003): Post-activation turn-off of NF-KB-dependent transcription is regulated by acetylation of p65. J Biol Chem 278: 2758-2766.
18.
Xavier RJ, Podolsky DK (2000): How to get along friendly microbes in hostile world. Science 289: 1483-1484.
19.
Hu EB, Zhang DG (2004): Reductive glutathione and ischemia reperfusion injury. J Navy Gen Hosp 17: 231-234.
20.
Desai A, Huang X, Warren JS (1999): Intracellular glutathione redox status modulates MCP-1 expression in pulmonary granulomatous vasculitis. Lab Invest 79: 837-847.
21.
Liu B, Andrieu-Abadie N, Levade T, et al. (1998): Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem 273: 11313-11320.
Share
RELATED ARTICLE
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
